-
1
-
-
0032861050
-
A rise in plasma creatinine that is not a sign of renal failure: Which drugs can be responsible?
-
Andreev E, Koopman M, and Arisz L (1999) A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 246:247-252.
-
(1999)
J Intern Med
, vol.246
, pp. 247-252
-
-
Andreev, E.1
Koopman, M.2
Arisz, L.3
-
4
-
-
84893844270
-
Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
-
Cefalu WT (2014) Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 124:485-487.
-
(2014)
J Clin Invest
, vol.124
, pp. 485-487
-
-
Cefalu, W.T.1
-
5
-
-
84941844370
-
Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat
-
Feinfeld DA, Fuh VL, and Safirstein R (1986) Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat. J Clin Chem Clin Biochem 24:529-532.
-
(1986)
J Clin Chem Clin Biochem
, vol.24
, pp. 529-532
-
-
Feinfeld, D.A.1
Fuh, V.L.2
Safirstein, R.3
-
6
-
-
84893872877
-
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
-
Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, and Woerle HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499-508.
-
(2014)
J Clin Invest
, vol.124
, pp. 499-508
-
-
Ferrannini, E.1
Muscelli, E.2
Frascerra, S.3
Baldi, S.4
Mari, A.5
Heise, T.6
Broedl, U.C.7
Woerle, H.J.8
-
7
-
-
8344257283
-
A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria
-
Francis J, Zhang J, Farhi A, Carey H, and Geller DS (2004) A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 19:2893-2895.
-
(2004)
Nephrol Dial Transplant
, vol.19
, pp. 2893-2895
-
-
Francis, J.1
Zhang, J.2
Farhi, A.3
Carey, H.4
Geller, D.S.5
-
8
-
-
84903639158
-
Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide
-
Frazier KS, Sobry C, Derr V, Adams MJ, Besten CD, Kimpe SD, Francis I, Gales TL, Haworth R, Maguire SR, et al. (2013) Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol 42:923-935.
-
(2013)
Toxicol Pathol
, vol.42
, pp. 923-935
-
-
Frazier, K.S.1
Sobry, C.2
Derr, V.3
Adams, M.J.4
Besten, C.D.5
Kimpe, S.D.6
Francis, I.7
Gales, T.L.8
Haworth, R.9
Maguire, S.R.10
-
9
-
-
79955158683
-
Systemic administration of PRO051 in duchenne's muscular dystrophy
-
Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
-
(2011)
N Engl J Med
, vol.364
, pp. 1513-1522
-
-
Goemans, N.M.1
Tulinius, M.2
Van Den Akker, J.T.3
Burm, B.E.4
Ekhart, P.F.5
Heuvelmans, N.6
Holling, T.7
Janson, A.A.8
Platenburg, G.J.9
Sipkens, J.A.10
-
10
-
-
0030918233
-
Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
-
Henry SP, Bolte H, Auletta C, and Kornbrust DJ (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120:145-155.
-
(1997)
Toxicology
, vol.120
, pp. 145-155
-
-
Henry, S.P.1
Bolte, H.2
Auletta, C.3
Kornbrust, D.J.4
-
11
-
-
84864811592
-
Renal uptake and tolerability of a 29-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey
-
Henry SP, Johnson M, Zanardi TA, Fey R, Auyeung D, Lappin PB, and Levin AA (2012) Renal uptake and tolerability of a 29-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology 301:13-20.
-
(2012)
Toxicology
, vol.301
, pp. 13-20
-
-
Henry, S.P.1
Johnson, M.2
Zanardi, T.A.3
Fey, R.4
Auyeung, D.5
Lappin, P.B.6
Levin, A.A.7
-
12
-
-
78751632457
-
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma
-
Herrington WG, Talbot DC, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, and Roberts IS (2011) Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis 57:300-303.
-
(2011)
Am J Kidney Dis
, vol.57
, pp. 300-303
-
-
Herrington, W.G.1
Talbot, D.C.2
Lahn, M.M.3
Brandt, J.T.4
Callies, S.5
Nagle, R.6
Winearls, C.G.7
Roberts, I.S.8
-
13
-
-
77957887958
-
Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity
-
Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, Hewitt P, and Mally A (2010) Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 277:49-58.
-
(2010)
Toxicology
, vol.277
, pp. 49-58
-
-
Hoffmann, D.1
Fuchs, T.C.2
Henzler, T.3
Matheis, K.A.4
Herget, T.5
Dekant, W.6
Hewitt, P.7
Mally, A.8
-
14
-
-
0033914834
-
Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans
-
Honing ML, Hijmering ML, Ballard DE, Yang YP, Padley RJ, Morrison PJ, and Rabelink TJ (2000) Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol 11: 1498-1504.
-
(2000)
J Am Soc Nephrol
, vol.11
, pp. 1498-1504
-
-
Honing, M.L.1
Hijmering, M.L.2
Ballard, D.E.3
Yang, Y.P.4
Padley, R.J.5
Morrison, P.J.6
Rabelink, T.J.7
-
15
-
-
84911492396
-
Empagliflozin for the treatment of type 2 diabetes
-
Jahagirdar V and Barnett AH (2014) Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 15:2429-2441.
-
(2014)
Expert Opin Pharmacother
, vol.15
, pp. 2429-2441
-
-
Jahagirdar, V.1
Barnett, A.H.2
-
16
-
-
84891878819
-
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2
-
Kasichayanula S, Liu X, Lacreta F, Griffen SC, and Boulton DW (2014) Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53:17-27
-
(2014)
Clin Pharmacokinet
, vol.53
, pp. 17-27
-
-
Kasichayanula, S.1
Liu, X.2
Lacreta, F.3
Griffen, S.C.4
Boulton, D.W.5
-
17
-
-
33750207033
-
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
-
Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, and Crooke RM (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114:1729-1735.
-
(2006)
Circulation
, vol.114
, pp. 1729-1735
-
-
Kastelein, J.J.1
Wedel, M.K.2
Baker, B.F.3
Su, J.4
Bradley, J.D.5
Yu, R.Z.6
Chuang, E.7
Graham, M.J.8
Crooke, R.M.9
-
18
-
-
84863259511
-
An overview of clinical safety experience of first- and second-generation antisense oligonucleotides
-
(Crooke ST ed) CRC Press, Boca Raton, FL
-
Kwoh TJ (2007) An overview of clinical safety experience of first- and second-generation antisense oligonucleotides, in Antisense Drug Technology: Principles, Strategies, and Application (Crooke ST ed), 365-399, CRC Press, Boca Raton, FL.
-
(2007)
Antisense Drug Technology: Principles, Strategies, and Application
, pp. 365-399
-
-
Kwoh, T.J.1
-
19
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
-
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, and Roth D; Modification of Diet in Renal Disease Study Group (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470.
-
(1999)
Ann Intern Med
, vol.130
, pp. 461-470
-
-
Levey, A.S.1
Bosch, J.P.2
Lewis, J.B.3
Greene, T.4
Rogers, N.5
Roth, D.6
-
20
-
-
84925283858
-
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
-
Limmroth V, Barkhof F, Desem N, Diamond MP, and Tachas G; ATL1102 Study Group (2014) CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 83:1780-1788.
-
(2014)
Neurology
, vol.83
, pp. 1780-1788
-
-
Limmroth, V.1
Barkhof, F.2
Desem, N.3
Diamond, M.P.4
Tachas, G.5
-
21
-
-
0014844684
-
Automated simultaneous determination of p-acetylaminohippurate and inulin in serum
-
Looyé A (1970) Automated simultaneous determination of p-acetylaminohippurate and inulin in serum. Clin Chem 16:753-755.
-
(1970)
Clin Chem
, vol.16
, pp. 753-755
-
-
Looyé, A.1
-
22
-
-
84893827104
-
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
-
Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509-514.
-
(2014)
J Clin Invest
, vol.124
, pp. 509-514
-
-
Merovci, A.1
Solis-Herrera, C.2
Daniele, G.3
Eldor, R.4
Fiorentino, T.V.5
Tripathy, D.6
Xiong, J.7
Perez, Z.8
Norton, L.9
Abdul-Ghani, M.A.10
-
23
-
-
0033060190
-
Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys
-
Monteith DK, Horner MJ, Gillett NA, Butler M, Geary R, Burckin T, Ushiro-Watanabe T, and Levin AA (1999) Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27:307-317.
-
(1999)
Toxicol Pathol
, vol.27
, pp. 307-317
-
-
Monteith, D.K.1
Horner, M.J.2
Gillett, N.A.3
Butler, M.4
Geary, R.5
Burckin, T.6
Ushiro-Watanabe, T.7
Levin, A.A.8
-
24
-
-
84869072637
-
Urinary N-acetyl-b-D-glucosaminidase levels are positively correlated with 2-hr plasma glucose levels during oral glucose tolerance testing in prediabetes
-
Ouchi M, Suzuki T, Hashimoto M, Motoyama M, Ohara M, Suzuki K, Igari Y, Watanabe K, Nakano H, and Oba K (2012) Urinary N-acetyl-b-D-glucosaminidase levels are positively correlated with 2-hr plasma glucose levels during oral glucose tolerance testing in prediabetes. J Clin Lab Anal 26:473-480.
-
(2012)
J Clin Lab Anal
, vol.26
, pp. 473-480
-
-
Ouchi, M.1
Suzuki, T.2
Hashimoto, M.3
Motoyama, M.4
Ohara, M.5
Suzuki, K.6
Igari, Y.7
Watanabe, K.8
Nakano, H.9
Oba, K.10
-
25
-
-
84869998632
-
Dapagliflozin: A review of its use in type 2 diabetes mellitus
-
Plosker GL (2012) Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 72:2289-2312.
-
(2012)
Drugs
, vol.72
, pp. 2289-2312
-
-
Plosker, G.L.1
-
26
-
-
0024600461
-
Indomethacin increases renal lithium reabsorption in man
-
Rabelink AJ, Koomans HA, Boer WH, Dorhout Mees EJ, and van Rijn HJ (1989) Indomethacin increases renal lithium reabsorption in man. Nephrol Dial Transplant 4:27-31.
-
(1989)
Nephrol Dial Transplant
, vol.4
, pp. 27-31
-
-
Rabelink, A.J.1
Koomans, H.A.2
Boer, W.H.3
Dorhout Mees, E.J.4
Van Rijn, H.J.5
-
27
-
-
84892576563
-
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
-
Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, and Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306:F188-F193.
-
(2014)
Am J Physiol Renal Physiol
, vol.306
, pp. F188-F193
-
-
Rieg, T.1
Masuda, T.2
Gerasimova, M.3
Mayoux, E.4
Platt, K.5
Powell, D.R.6
Thomson, S.C.7
Koepsell, H.8
Vallon, V.9
-
28
-
-
10744229025
-
Molecular analysis of the SGLT2 gene in patients with renal glucosuria
-
Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, et al. (2003) Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873-2882.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 2873-2882
-
-
Santer, R.1
Kinner, M.2
Lassen, C.L.3
Schneppenheim, R.4
Eggert, P.5
Bald, M.6
Brodehl, J.7
Daschner, M.8
Ehrich, J.H.9
Kemper, M.10
-
29
-
-
84924415690
-
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
-
Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, and Mittleman RS (2013) Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 36:566-575.
-
(2013)
Eur Heart J
, vol.36
, pp. 566-575
-
-
Santos, R.D.1
Duell, P.B.2
East, C.3
Guyton, J.R.4
Moriarty, P.M.5
Chin, W.6
Mittleman, R.S.7
-
30
-
-
84918546698
-
Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
-
Scheen AJ and Paquot N (2014) Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab 40(6, Suppl 1): S4-S11.
-
(2014)
Diabetes Metab
, vol.40
, Issue.6
, pp. S4-S11
-
-
Scheen, A.J.1
Paquot, N.2
-
31
-
-
84919649970
-
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes
-
Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, and Rothenberg P (2014) Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 9:e110069.
-
(2014)
PLoS One
, vol.9
-
-
Sha, S.1
Devineni, D.2
Ghosh, A.3
Polidori, D.4
Hompesch, M.5
Arnolds, S.6
Morrow, L.7
Spitzer, H.8
Demarest, K.9
Rothenberg, P.10
-
32
-
-
84860238875
-
Nephrotoxicity of hexachloro-1:3-butadiene in the male hanover wistar rat; correlation of minimal histopathological changes with biomarkers of renal injury
-
Swain A, Turton J, Scudamore C, Maguire D, Pereira I, Freitas S, Smyth R, Munday M, Stamp C, Gandhi M, et al. (2012) Nephrotoxicity of hexachloro-1:3-butadiene in the male Hanover Wistar rat; correlation of minimal histopathological changes with biomarkers of renal injury. J Appl Toxicol 32:417-428.
-
(2012)
J Appl Toxicol
, vol.32
, pp. 417-428
-
-
Swain, A.1
Turton, J.2
Scudamore, C.3
Maguire, D.4
Pereira, I.5
Freitas, S.6
Smyth, R.7
Munday, M.8
Stamp, C.9
Gandhi, M.10
-
33
-
-
0029618259
-
Conventional measurement of renal function utilizing serum creat-inine, creatinine clearance, inulin and para-aminohippuric acid clearance
-
discussion 503-504
-
Toto RD (1995) Conventional measurement of renal function utilizing serum creat-inine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens 4:505-509, discussion 503-504
-
(1995)
Curr Opin Nephrol Hypertens
, vol.4
, pp. 505-509
-
-
Toto, R.D.1
-
34
-
-
77952160766
-
Kidney injury molecule-1outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies
-
Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, et al. (2010) Kidney injury molecule-1outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28:478-485.
-
(2010)
Nat Biotechnol
, vol.28
, pp. 478-485
-
-
Vaidya, V.S.1
Ozer, J.S.2
Dieterle, F.3
Collings, F.B.4
Ramirez, V.5
Troth, S.6
Muniappa, N.7
Thudium, D.8
Gerhold, D.9
Holder, D.J.10
-
35
-
-
84929954732
-
First proof of pharmacology in humans of a novel glucagon receptor antisense drug
-
van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, Cohen AF, Bhanot S, and Burggraaf J (2015) First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol 55:298-306.
-
(2015)
J Clin Pharmacol
, vol.55
, pp. 298-306
-
-
Van Dongen, M.G.1
Geerts, B.F.2
Morgan, E.S.3
Brandt, T.A.4
De Kam, M.L.5
Romijn, J.A.6
Cohen, A.F.7
Bhanot, S.8
Burggraaf, J.9
-
36
-
-
84884534231
-
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9
-
van Poelgeest EP, Swart RM, Betjes MGH, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, and Burggraaf J (2013) Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 62: 796-800.
-
(2013)
Am J Kidney Dis
, vol.62
, pp. 796-800
-
-
Van Poelgeest, E.P.1
Swart, R.M.2
Betjes, M.G.H.3
Moerland, M.4
Weening, J.J.5
Tessier, Y.6
Hodges, M.R.7
Levin, A.A.8
Burggraaf, J.9
-
37
-
-
84901359283
-
Urinary kidney bio-markers for early detection of nephrotoxicity in clinical drug development
-
van Meer L, Moerland M, Cohen AF, and Burggraaf J (2014) Urinary kidney bio-markers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol 77:947-957.
-
(2014)
Br J Clin Pharmacol
, vol.77
, pp. 947-957
-
-
Van Meer, L.1
Moerland, M.2
Cohen, A.F.3
Burggraaf, J.4
-
39
-
-
0016153194
-
Simplified measurement of p-aminohippurate and other arylamines in plasma and urine
-
Waugh WH and Beall PT (1974) Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. Kidney Int 5:429-436.
-
(1974)
Kidney Int
, vol.5
, pp. 429-436
-
-
Waugh, W.H.1
Beall, P.T.2
-
40
-
-
84867619259
-
Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second generation antisense oligonucleotide that targets the human sodium glucose cotransporter 2 (SGLT2)
-
Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, and Henry SP (2012) Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second generation antisense oligonucleotide that targets the human sodium glucose cotransporter 2 (SGLT2). J Pharmacol Exp Ther 343:489-496
-
(2012)
J Pharmacol Exp Ther
, vol.343
, pp. 489-496
-
-
Zanardi, T.A.1
Han, S.C.2
Jeong, E.J.3
Rime, S.4
Yu, R.Z.5
Chakravarty, K.6
Henry, S.P.7
|